Genprex reveals slew of recent milestones as it plans for upcoming clinical trials

Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive’s Christine Corrado about the Texas-based biotechnology company’s most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as Oncoprex. What’s more, its ramping up the production of its drug for upcoming clinical trials, and the company has joined the Russell 3000 index.